ABCC2基因过表达对肺腺癌预后的影响

来源期刊：广州医药 | 109-118 发布时间：2022-11-30 收稿时间：2025/11/13 18:15:26 阅读量：24

作者：: 方子晗,

喻祖豪,

刘颖,

杨振,

王可,

关键词：: ABCC2 肺腺癌预后 TCGA数据库 GSEA; ABCC2 lung adenocarcinoma prognosis TCGA database GSEA

DOI：: 10.3969/j.issn.1000-8535.2022.06.023

收稿时间：: 2022-02-03
修订日期：
接收日期：
引用总数：: 2

目的分析ABCC2基因表达水平与肺腺癌预后之间的关联性,并对其影响机制进行初步探索。方法采用TCGA数据库和HPA数据库对肺腺癌病人癌组织和癌旁组织基因表达数据进行差异性分析,单因素及多因素COX回归评估ABCC2与肺腺癌预后之间的关联性,GSEA用于探讨与ABCC2显著关联的信号通路。结果 ABCC2在肺腺癌肿瘤组织中存在过表达现象,Kaplan-Meier生存分析曲线结果显示ABCC2基因过表达使肺腺癌病人的死亡风险显著升高(HR=1.46,95%CI=1.09~1.95; P=0.010)。单因素及多因素COX回归结果显示ABCC2基因过表达是肺腺癌病人不良预后的独立危险因素。GSEA结果显示ABCC2可能通过调节药物代谢从而对肺腺癌的发展进行调控。结论 ABCC2基因过表达使肺腺癌病人的死亡风险显著升高,ABCC2可能是肺腺癌不良预后的潜在分子生物标志物。

1、 SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.

2、 ARRITETA O,LAZCANO E. Lung cancer.Epidemiology,diagnosis and treatment[J].Salud Publica Mex,2019,61(3): 217-218.

3、 ALEXANDER M,KIM S Y,CHENG H. Update 2020: Management of Non-Small Cell Lung Cancer[J].Lung,2020,198(6):897-907.

4、刘盈,黄凤祥,陈红杰,等. 基于数据库挖掘UBE2C在肺腺癌中的表达及其临床意义[J].中南大学学报(医学版),2020,45(9):1044-1052.

5、 FOIS S S,PALIOGIANNIS P,ZINELLU A,et al.Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer[J].Int J Mol Sci,2021,22(2):612.

6、 HUANG Y S,CHANG T E,PERNG C L,et al.The association of transporter ABCC2 (MRP2) genetic variation and drug-induced hyperbilirubinemia[J].J Chin Med Assoc,2021,84(2):129-135.

7、 WISSEL G,DENG F,KUDRYAVTSEV P,et al.A structure-activity relationship study of ABCC2 inhibitors[J].Eur J Pharm Sci,2017(103):60-69.

8、 CHEN Y,ZHOU H,YANG S,et al.Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer[J].Cell Biochem Funct,2021,39(2):277-286.

9、 WEI D,ZHANG H,PENG R,et al.ABCC2 (1249G>A) polymorphism implicates altered transport activity for sorafenib[J].Xenobiotica,2017,47(11):1008-1014.

10、 DIGRE A,LINDSKOG C. The Human Protein Atlas-Spatial localization of the human proteome in health and disease[J].Protein Sci,2021,30(1):218-233.

11、 GEISTLINGER L,CSABA G,SANTARELLI M,et al.Toward a gold standard for benchmarking gene set enrichment analysis[J].Brief Bioinform,2021,22(1):545-556.

12、 CLARKE M F,DICK J E,DIRKS P B,et al.Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells[J].Cancer Res,2006,66(19):9339-9344.

13、 DEAN M. ABC transporters,drug resistance,and cancer stem cells[J].J Mammary Gland Biol Neoplasia,2009,14(1):3-9.

14、 KORITA P V,WAKAI T,SHIRAI Y,et al.Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma[J].Oncol Rep,2010,23(4):965-972.

15、 BüCHLER M,K?NIG J,BROM M,et al.cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein,cMrp,reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats[J].J Biol Chem,1996,271(25):15091-15098.

16、 SUZUKI H,SUGIYAMA Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition[J].Adv Drug Deliv Rev,2002,54(10):1311-1331.

17、 ROST D,MAHNER S,SUGIYAMA Y,et al.Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine[J].Am J Physiol Gastrointest Liver Physiol,2002,282(4):G720-G726.

18、 ITO K,OLESCHUK C J,WESTLAKE C,et al.Mutation of Trp1254 in the multispecific organic anion transporter,multidrug resistance protein 2 (MRP2) (ABCC2),alters substrate specificity and results in loss of methotrexate transport activity[J].J Biol Chem,2001,276(41):38108-38114.

19、 LIU Y,YIN Y,SHENG Q,et al.Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia[J].PLoS One,2014,9(1):e82681.

20、 ANDERSEN V,VOGEL L K,KOPP T I,et al.High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence[J].PLoS One,2015,10(3):e0119255.

21、 KUMAR A,JAITAK V. Natural products as multidrug resistance modulators in cancer[J].Eur J Med Chem,2019(176):268-291.

22、 QIAN L,FANG S,YAN Y L,et al.The ABCC2 c. -24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis[J].J Clin Neurosci,2017(37):6-14.

23、 KARTAL-YANDIM M,ADAN-GOKBULUT A,BARAN Y. Molecular mechanisms of drug resistance and its reversal in cancer[J].Crit Rev Biotechnol,2016,36(4):716-726.

24、 SHARIFI M J,BAHOUSH G,ZAKER F,et al.Association of -24CT,1249GA,and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia[J].Pediatr Hematol Oncol,2014,31(2):169-177.

25、 SUN L,KE J,HE Z,et al.HES1 Promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins[J].J Cancer,2017,8(14):2802-2808.

26、 ZHANG D,DING L,LI Y,et al.Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumor cells[J].Sci Rep,2017,7(1):16231.

27、 CAO K N,REN G H,LU C C,et al.ABCC2 c. -24 C>T sing- le-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects[J].Eur J Clin Pharmacol,2020,76(1):51-59.

28、潘霞,王智慧,雷小勇. microRNAs与ABC转运蛋白介导的肿瘤多药耐药研究进展[J].中华肿瘤防治杂志,2015,22(8):644-648.

29、 CHEN Y,ZHOU H,YANG S,et al.Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer[J].Cell Biochem Funct,2021,39(2):277-286.

30、 CUFFE S,AZAD A K,QIU X,et al.ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR. 24 trial of platinum-treated advanced stage non-small cell lung cancer patients[J].Cancer Epidemiol,2016(41):50-56.

1、金山. 肺腺癌免疫治疗的预测标志物及其增敏中药筛选的研究[D]. 大理大学,2024.

2、陈启宪,何卫国,何丽美,等.GRB14基因在肺腺癌中的表达及对预后的影响[J].广州医药,2025,56(11):1482-1490+1500.DOI:10.20223/j.cnki.1000-8535.2025.11.003.